BioAtla Inc
BCAB
Get informed when a big investor buys or sells
+ FollowMarket Cap$5.13M
Close$
$-0.59
117.2% downside
Current Fair Value
117.2% downsideOvervalued by 117.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $5.13 Million |
|---|---|
| Enterprise Value | $9.45 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-50.5 |
| Beta | 0.76 |
| Outstanding Shares | 1,660,586 |
Return
| Return on Equity | 25.75% |
|---|---|
| Return on Assets | -98.17% |
| Return on Invested Capital | 264.01% |
Valuation & Multiples
| P/E Ratio | -0.12 |
|---|---|
| PEG | 0.12 |
| Price to Sales | 0.69 |
| Price to Book Ratio | -0.16 |
| Enterprise Value to Revenue | 1.11 |
| Enterprise Value to EBIT | -0.31 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0.62 |
| Debt to Equity | -0.16 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 13, 2026
EPS Estimate
$-8.50
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 18, 2026
EPS Estimate
$-7.00
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | 108,100▲ 856.64% |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 20.48%▼ 1.92% |
|---|---|
| Total Invested | $2.47M▼ 67.05% |
| Investors Holding | 36▼ 5.00% |
ESG Score
No data
About BioAtla Inc
36 employeesBioAtla® is a San Diego biotech company that develops novel monoclonal antibody and cell based therapeutics using our proprietary Conditionally Active Biologics™ (CAB) and Comprehensive Integrated Antibody Optimization (CIAO!™) platforms...